AquaBounty Technologies on Thursday announced it appointed Rick Sterling as a non-executive director to its board of directors.
Sterling has served as CFO of Intrexon since 2007. Prior to joining Intrexon, he was with KPMG where he worked in the audit practice for more than 17 years, and where he served private and public company clients primarily in the healthcare, technology and manufacturing industries.
The U.S.-based company also announced financial results for the first half of 2013, posting a loss of USD 2.05 million (EUR 1.5 million), down from a USD 2.4 million (EUR 1.8 million) loss for the same period last year.
Operating expenses were lower at USD 2.1 million (EUR 1.6 million), down from USD 2.4 million in the first half of 2012, reflecting the company's continued tight spending control. However, cash used in the first half of 2013 was higher than the comparable period in 2012 at USD 2.1 million, up from USD 1.8 million (EUR 1.35 million), due primarily to a deposit payment on the lease renewal of the company’s grow-out facility in Panama.
“We remain confident of receiving approval for our new animal drug application for AquAdvantage Salmon. The basis of our confidence is that, since the public meetings in September 2010, there hasn't been a single new substantive scientific or legal argument presented to the FDA against our application,” said Rob Stotish, CEO. “This makes us hopeful that the strength of law, due process and science-based regulation will prevail, and approval will be granted.”
Sterling has served as CFO of Intrexon since 2007. Prior to joining Intrexon, he was with KPMG where he worked in the audit practice for more than 17 years, and where he served private and public company clients primarily in the healthcare, technology and manufacturing industries.
The U.S.-based company also announced financial results for the first half of 2013, posting a loss of USD 2.05 million (EUR 1.5 million), down from a USD 2.4 million (EUR 1.8 million) loss for the same period last year.
Operating expenses were lower at USD 2.1 million (EUR 1.6 million), down from USD 2.4 million in the first half of 2012, reflecting the company's continued tight spending control. However, cash used in the first half of 2013 was higher than the comparable period in 2012 at USD 2.1 million, up from USD 1.8 million (EUR 1.35 million), due primarily to a deposit payment on the lease renewal of the company’s grow-out facility in Panama.
“We remain confident of receiving approval for our new animal drug application for AquAdvantage Salmon. The basis of our confidence is that, since the public meetings in September 2010, there hasn't been a single new substantive scientific or legal argument presented to the FDA against our application,” said Rob Stotish, CEO. “This makes us hopeful that the strength of law, due process and science-based regulation will prevail, and approval will be granted.”
